HC Wainwright Has Negative Outlook of Belite Bio Q1 Earnings

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued on Tuesday, March 3rd. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.71) per share for the quarter, down from their prior estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at $4.05 EPS and FY2026 earnings at $1.89 EPS.

A number of other brokerages also recently commented on BLTE. Wall Street Zen downgraded shares of Belite Bio from a “hold” rating to a “sell” rating in a research note on Sunday, January 4th. Benchmark restated a “buy” rating on shares of Belite Bio in a research note on Tuesday. Cantor Fitzgerald raised their price objective on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a research report on Tuesday. Maxim Group set a $200.00 target price on shares of Belite Bio in a report on Tuesday, December 2nd. Finally, Morgan Stanley increased their price target on shares of Belite Bio from $191.00 to $201.00 and gave the company an “overweight” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Belite Bio has an average rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Stock Performance

NASDAQ:BLTE opened at $172.57 on Friday. The firm has a 50-day simple moving average of $169.74 and a 200-day simple moving average of $124.02. Belite Bio has a one year low of $49.00 and a one year high of $200.00. The firm has a market cap of $6.47 billion, a P/E ratio of -75.03 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18.

Institutional Investors Weigh In On Belite Bio

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in Belite Bio in the 3rd quarter worth approximately $370,000. High Net Worth Advisory Group LLC acquired a new stake in shares of Belite Bio during the third quarter worth $259,000. GAMMA Investing LLC grew its holdings in shares of Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock valued at $130,000 after buying an additional 176 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Belite Bio in the 2nd quarter valued at $190,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of Belite Bio in the 2nd quarter valued at $147,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.